IMBCR & Emory University’s Big Discovery!
Multiple myeloma (MM) patients are at higher risk for severe COVID-19. Their mRNA vaccination response…
read moreEfficacy and Safety of Ruxolitinib and Steroids for Treating Patients with Relapsed or Refractory Multiple Myeloma (RRMM). Results from the I-RUX Study Published in ASH2020
January 19, 2021 WEST HOLLYWOOD, CA, January 19, 2021 – ONCOtherapeutics and Dr. James Berenson…
read moreJames R. Berenson, MD, Inc. Announces Rebranding and Changes Organization Name to Berenson Cancer Center
New name, logo, and business unit alignment introduced as part of an extensive rebranding initiative…
read moreTreatment of Patients with Relapsed/Refractory Multiple Myeloma with Ruxolitinib, Methylprednisolone and Lenalidomide
Treatment of Patients with Relapsed/Refractory Multiple Myeloma with Ruxolitinib, Methylprednisolone and Lenalidomide: Using Changes in…
read moreA Pilot Study Examining Selinexor’s Ability to Overcome Resistance in Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy
A Pilot Study Examining Selinexor’s Ability to Overcome Resistance in Multiple Myeloma Patients Who Are…
read moreA Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients
A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients Sponsor: Incyte Protocol…
read moreA Phase 2, Open Label, Randomized Trial Evaluating Ixazomib Compared to Ixazomib-Lenalidomide
A Phase 2, Open Label, Randomized Trial Evaluating Ixazomib Compared to Ixazomib-Lenalidomide Combination Maintenance Therapy…
read more